Patients Infected with HIV Type 1 Subtype CRF01_AE and Failing First-Line Nevirapine- and Efavirenz-Based Regimens Demonstrate Considerable Cross-Resistance to Etravirine
Restricted accessLetterFirst published online June, 2010
Patients Infected with HIV Type 1 Subtype CRF01_AE and Failing First-Line Nevirapine- and Efavirenz-Based Regimens Demonstrate Considerable Cross-Resistance to Etravirine
HammerSM, EronJJJr, ReissPet al.Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA, 2008; 300,5:555–570.
2.
VingerhoetsJ, AzijnH, FransenEet al.TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J Virol, 2005; 79,20:12773–12782.
3.
LazzarinA, CampbellT, ClotetBet al.Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, 2007; 370,9581:39–48.
4.
MadrugaJV, CahnP, GrinsztejnBet al.Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, 2007; 370,9581:29–38.
5.
VingerhoetsJ, PeetersM, AzijnHet al.An update on the list of NNRTI mutations associated with decreased virological response to etravirine: Multivariate analysis on the pooled DUET-1 and DUET-2 clinical trial data. Antivir Ther, 2008; 13,Suppl 3:A26
6.
HemelaarJ, GouwsE, GhysPD, OsmanovS. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS, 2006; 20,16:W13–W23.
7.
LlibreJM, SantosJR, PuigTet al.Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J Antimicrob Chemother, 2008; 62,5:909–913.
8.
SungkanuparphS, ManosuthiW, KiertiburanakulS, PiyavongB, ChantratitaW. Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting. Curr HIV Res, 2008; 6,5:474–476.
9.
HirschMS, GunthardHF, SchapiroJMet al.Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis, 2008; 47,2:266–285.
10.
Martinez-CajasJL, Pant-PaiN, KleinMB, WainbergMA. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: A systematic review of virologic and biochemical evidence. AIDS Rev, 2008; 10,4:212–223.
11.
Kosakovsky PondSL, SmithDM. Are all subtypes created equal? The effectiveness of antiretroviral therapy against non-subtype B HIV-1. Clin Infect Dis, 2009; 48,9:1306–1309.
12.
SungkanuparphS, AnekthananonT, HiransuthikulNet al.Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: The recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai, 2008; 91,12:1925–1935.
13.
RichmanDD, HavlirD, CorbeilJet al.Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol, 1994; 68,3:1660–1666.
LapadulaG, CalabresiA, CastelnuovoFet al.Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors. Antivir Ther, 2008; 13,4:601–605.
16.
Scaling up Antiretroviral Therapy in Resource-Limited Settings. Treatment Guidelines for a Public Health Approach. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO), 2006revision.
17.
BoothCL, GerettiAM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother, 2007; 59,6:1047–1056.
18.
SmithDM, WongJK, ShaoHet al.Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: Implications for secondary transmission. J Infect Dis, 2007; 196,3:356–360.
